Serum Fibroblast Growth Factor-23 (FGF-23) and Fracture Risk in Elderly Men
(2011) In Journal of Bone and Mineral Research 26(4). p.857-864- Abstract
- A normal mineral metabolism is integral for skeletal development and preservation of bone integrity. Fibroblast growth factor 23 (FGF-23) is a bone-derived circulating factor that decreases serum concentrations of inorganic phosphorous (P-i) and 1,25-dihydroxyvitamin D-3 [1,25(OH)(2)D-3]. Increased FGF-23 expression is a direct or indirect culprit in several skeletal disorders; however, the relation between FGF-23 and fracture risk remains undetermined. We evaluated the prospective relation between serum intact FGF-23 (measured by a two-site monoclonal antibody ELISA) and fracture risk employing the Swedish part of the population-based Osteoporotic Fractures in Men Study (MrOS; n = 2868; mean age 75.4 +/- 3.2 years; median follow-up period... (More)
- A normal mineral metabolism is integral for skeletal development and preservation of bone integrity. Fibroblast growth factor 23 (FGF-23) is a bone-derived circulating factor that decreases serum concentrations of inorganic phosphorous (P-i) and 1,25-dihydroxyvitamin D-3 [1,25(OH)(2)D-3]. Increased FGF-23 expression is a direct or indirect culprit in several skeletal disorders; however, the relation between FGF-23 and fracture risk remains undetermined. We evaluated the prospective relation between serum intact FGF-23 (measured by a two-site monoclonal antibody ELISA) and fracture risk employing the Swedish part of the population-based Osteoporotic Fractures in Men Study (MrOS; n = 2868; mean age 75.4 +/- 3.2 years; median follow-up period 3.35 years). The incidence of at least one validated fracture after baseline was 20.4 per 1000 person-years. FGF-23 was directly related to the overall fracture risk [age-adjusted hazard ratio (HR) per SD increase = 1.20, 95% confidence interval (CI) 1.03-1.40] and vertebral fracture risk (HR = 1.33, 95% CI 1.02-1.75). Spline models revealed a nonlinear relation between FGF-23 and fracture risk, with the strongest relation at FGF-23 levels above 55.7 pg/mL. FGF-23 levels above 55.7 pg/mL also were associated with an increased risk for hip and nonvertebral fractures (HR = 2.30, 95% CI 1.16-4.58, and HR = 1.63, 95% CI 1.01-2.63, respectively). These relations remained essentially unaltered after adjustment for bodymass index (BMI), bone mineral density (BMD), glomerular filtration rate, 25(OH)(2)D-3, parathyroid hormone (PTH), and other fracture risk factors. In conclusion, FGF-23 is a novel predictor of fracture risk in elderly men. (C) 2011 American Society for Bone and Mineral Research. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/1925284
- author
- Mirza, Majd Ai ; Karlsson, Magnus LU ; Mellstrom, Dan ; Orwoll, Eric ; Ohlsson, Claes ; Ljunggren, Osten and Larsson, Tobias E.
- organization
- publishing date
- 2011
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- FGF-23, FRACTURES, BONE MINERAL DENSITY, BMD, VITAMIN D, CALCITRIOL, RICKETS, OSTEOMALACIA
- in
- Journal of Bone and Mineral Research
- volume
- 26
- issue
- 4
- pages
- 857 - 864
- publisher
- Wiley-Blackwell
- external identifiers
-
- wos:000288861400020
- scopus:79953046736
- pmid:20928885
- ISSN
- 1523-4681
- DOI
- 10.1002/jbmr.263
- language
- English
- LU publication?
- yes
- id
- 291fdd38-7335-405a-a9c3-9d358699f869 (old id 1925284)
- date added to LUP
- 2016-04-01 10:49:13
- date last changed
- 2025-10-14 12:00:40
@article{291fdd38-7335-405a-a9c3-9d358699f869,
abstract = {{A normal mineral metabolism is integral for skeletal development and preservation of bone integrity. Fibroblast growth factor 23 (FGF-23) is a bone-derived circulating factor that decreases serum concentrations of inorganic phosphorous (P-i) and 1,25-dihydroxyvitamin D-3 [1,25(OH)(2)D-3]. Increased FGF-23 expression is a direct or indirect culprit in several skeletal disorders; however, the relation between FGF-23 and fracture risk remains undetermined. We evaluated the prospective relation between serum intact FGF-23 (measured by a two-site monoclonal antibody ELISA) and fracture risk employing the Swedish part of the population-based Osteoporotic Fractures in Men Study (MrOS; n = 2868; mean age 75.4 +/- 3.2 years; median follow-up period 3.35 years). The incidence of at least one validated fracture after baseline was 20.4 per 1000 person-years. FGF-23 was directly related to the overall fracture risk [age-adjusted hazard ratio (HR) per SD increase = 1.20, 95% confidence interval (CI) 1.03-1.40] and vertebral fracture risk (HR = 1.33, 95% CI 1.02-1.75). Spline models revealed a nonlinear relation between FGF-23 and fracture risk, with the strongest relation at FGF-23 levels above 55.7 pg/mL. FGF-23 levels above 55.7 pg/mL also were associated with an increased risk for hip and nonvertebral fractures (HR = 2.30, 95% CI 1.16-4.58, and HR = 1.63, 95% CI 1.01-2.63, respectively). These relations remained essentially unaltered after adjustment for bodymass index (BMI), bone mineral density (BMD), glomerular filtration rate, 25(OH)(2)D-3, parathyroid hormone (PTH), and other fracture risk factors. In conclusion, FGF-23 is a novel predictor of fracture risk in elderly men. (C) 2011 American Society for Bone and Mineral Research.}},
author = {{Mirza, Majd Ai and Karlsson, Magnus and Mellstrom, Dan and Orwoll, Eric and Ohlsson, Claes and Ljunggren, Osten and Larsson, Tobias E.}},
issn = {{1523-4681}},
keywords = {{FGF-23; FRACTURES; BONE MINERAL DENSITY; BMD; VITAMIN D; CALCITRIOL; RICKETS; OSTEOMALACIA}},
language = {{eng}},
number = {{4}},
pages = {{857--864}},
publisher = {{Wiley-Blackwell}},
series = {{Journal of Bone and Mineral Research}},
title = {{Serum Fibroblast Growth Factor-23 (FGF-23) and Fracture Risk in Elderly Men}},
url = {{http://dx.doi.org/10.1002/jbmr.263}},
doi = {{10.1002/jbmr.263}},
volume = {{26}},
year = {{2011}},
}